Brian I. Rini, MD | Authors

Articles

Follow-Up Shows Continued Efficacy in RCC With Pembrolizumab/Axitinib

July 07, 2021

Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.

Selecting Atezolizumab Plus Bevacizumab Versus Ipilimumab Plus Nivolumab in RCC

October 26, 2018

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.

Rationale for Combining Atezolizumab/Bevacizumab in mRCC

July 16, 2018

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma in the IMmotion151trial.